Related by context. All words. (Click for frequent words.) 78 xxi 71 xviii 71 xix 71 xxvii 70 xvi 70 xxiii 70 xvii 70 xxiv 70 xiii 70 xxvi 69 viii 69 xxv 68 xii 67 xxviii 67 vii 66 xv 65 iv 63 xiv 63 ix 63 iii 62 Immtech clinical trials 61 xxxii 58 Immtech scientists 58 vi 58 xi 58 collect reinsurance recoverables 58 xxxiii 57 risksassociated 56 aresubject 56 affecting mortality morbidity 56 adverse determinations 56 materially adversely affect 56 thereby negatively impacting 56 general economicconditions 55 changesin 55 incur unanticipated 55 otherfactors 54 ii 54 DSL.net s 54 limitedto 54 ourability 54 Crisa acquisition 54 consummating acquisitions 54 notlimited 54 requirements xxii 54 adversely affect 53 risks associatedwith 53 nonoccurrence 53 expenses associated therewith 53 involverisks 53 affecting Amarin 53 xxix 53 SeraCare competitors 53 adversely affect Waste Connections 53 substantial indebtedness 53 economicconditions 53 contingent guaranties 53 regarding Heska 52 multiple lease terminations 52 withrespect 52 including withoutlimitation 52 PharMerica LTC Transaction 52 EMPOWER pivotal trial 52 causeactual results 52 VIOXX Lawsuits 52 statementsregarding 52 prepayment speeds loan originations 52 associatedwith 52 tenant bankruptcies 52 persistency mortality 52 Erythropoietic therapies may 52 differ materiallyfrom 52 impactof 51 vii IBC 51 Unitholder liability 51 PLAVIX R patent 51 successfully integrate 51 arenot limited 51 ultimate recoverability 51 legal proceedings xxi 51 FierceGovernmentIT tracks 51 ability tosuccessfully 51 d Reflects 51 work stoppages quarantines 51 Pure Biofuels ability 51 Market Disruption 51 Thalomid R 51 couldcause actual results 51 GUIDANCE AND 50 maydiffer materially 50 risks anduncertainties 50 affirmative covenants 50 manufacture PolyHeme 50 relatedto 50 capture exosomes 50 affecting Pennichuck Corporation 50 Auxilium anticipates 50 differmaterially 50 lender consents 50 mergers dispositions 50 market PolyHeme commercially 50 i# implanters 50 anduncertainties 50 CCR5 inhibitors entry 50 SANCTURA SANCTURA XR NEBIDO 50 orother 50 unfavorable geologic 50 CAUTION ANY ATTEMPT 50 areforward looking 49 tarmac strandings Hanni 49 marketconditions 49 uncertainties materialize Shire plc 49 impacting WesBanco 49 uncertainties materialize Shire 49 unanticipated 49 orotherwise 49 BiDil XR drug 49 difficulties foreseeing 49 Shire plc Attention Deficit 49 f h 49 CholeraGarde R Peru 49 relating 49 uncertaintiesthat 49 commercialize ZYFLO CR 49 serious cardiovascular thrombotic 49 negatively impact 49 unitholder liability 49 BY AN ENTRANT 49 Candente relies upon 49 NxStage anticipates 49 party VLSI fabrication 49 Excluding acquisitions divestitures 49 incurrence 49 retrocessional coverage 49 inventory obsolescence 49 permitting timelines 49 work stoppages slowdowns 49 SUPPRELIN LA DELATESTRYL 49 #.#-# b [002] 49 delinquencies defaults 49 reinsurance recoverables owed 49 Questcor intellectual property 49 SANCTURA SANCTURA XR VANTAS 49 market fluctuations investee 49 PolyHeme successfully 49 brine inflows 49 gastrointestinal GVHD include 49 positive inotropic agents 48 borrower depositor 48 without limitation 48 adversely affect Univest Corporation 48 Chase Kishner 48 TP# CETi 1 48 timing rescheduling 48 EPIXTAR 'S 48 arebased 48 HANA MAX 48 ofsuch 48 ourproducts 48 adversely impact 48 maycause 48 c Relates 48 suchforward looking 48 expropriation nationalization 48 filingswith 48 toreflect 48 xxxi 48 AngelCiti expectations 48 Risks uncertainties 48 d Represents 48 associated therewith 48 reasonably determinable 48 deploy MDCE services 48 ADSI reliance 48 resultof 48 MGCD# MGCD# [002] 48 Sepracor anticipates 48 Shire Attention Deficit 48 affecting BEO Bancorp 48 prepayment speeds loan 48 Fampridine SR Acorda Therapeutics 48 subjectto 48 unanticipated difficulties 48 xiv licensing 48 xi unanticipated 48 mergers consolidations 48 futureresults 48 indebtedness covenant 48 Somaxon ability 48 CORLUX CORT # 48 Nortel unfunded 48 MGCD# MGCD# [001] 48 vii Dynamic 47 uncertainties materializes FICO 47 differ materially fromthose 47 VimpelCom disclaims 47 postretirement benefit obligations 47 expressed orimplied 47 TriPath Oncology 47 xv licensing 47 theCompany 47 TrueKnowledge Platform TM 47 Phyto Source LP 47 HealthGate ability 47 technological innovations adversely affecting 47 intercompany arrangements 47 prices drydocking 47 xiv unanticipated 47 affect Petroflow 47 adversely affect FNB 47 suchstatements 47 Congoleum undertakes 47 nonhematologic adverse reactions 47 especially Copaxone ® 47 TRIOLEX HE# APOPTONE HE# 47 TranSwitch indebtedness 47 thepotential 47 Safe Harbors created 47 impair FPL 47 Slightly offsetting 47 - -Billeaudeau 47 successfully commercialize Silenor 47 cadence regulatory approvals 47 refinance indebtedness 47 Mago ® 47 Colo. Sess 47 theability 47 risksand uncertainties 47 Nortel strategic alliances 47 Intervoice cautions 47 i g 47 iii Cubist 47 Discontinuations due 47 related thereto 47 af fected 47 Projects Initiation 47 materially adversely affected 47 affect Pennichuck Corporation 47 Detrex stock 47 b Represents 47 PLIVA acquisition 47 x fluctuating beryllium 47 involve risksand uncertainties 47 h g 47 Cautionary Disclosures 46 andgeneral 46 MTI MTI Micro 46 without limitation Terremark 46 XL# anticancer compounds 46 EVIZON TM squalamine lactate 46 c Excludes 46 breast tenderness bloating 46 couldcause 46 n h r 46 render PolyHeme obsolete 46 vii viii 46 Dynegy cautions 46 Varvarinskoye Project 46 LOPROX R 46 surety bonding increased 46 bone marrow fibrosis 46 Bioaccelerate compounds under 46 retail industries repositionings 46 OSI Pharmaceuticals filings 46 #.#-# Equal Opportunity 46 PGP Acquisition 46 rapid technological 46 #.#-# b [001] 46 torsemide ER 46 Prelude SkinPrep Systems 46 VYVANSE TM lisdexamfetamine 46 h r 46 events thrombocytopenia neutropenia 46 vi vii 46 SearchHelp communications 46 Miraculins cautions 46 theseforward looking 46 Gastroesophageal Reflux 46 BioSante licensees 46 withoutlimitation 46 b Excludes 46 cancellations rescheduling 46 adversely affect Hologic 46 Form #KSB filed 46 involve risks anduncertainties 46 MultiCell bases 46 andoperating 46 Company noncontributory defined 46 Protonix ® 46 AspenTech periodic reports 46 TRISENOX R 46 LAE reserves 46 FINANCIAL CONDITION AND 46 cause actualresults 46 competitively procured pursuant 46 Analysis C.1 Strengths 46 CompAir acquisition 46 regardingthe 46 natural disasters epidemics 46 consolidations restructurings bankruptcies 46 unanticipated geological 46 acquisitions dispositions 46 Unanticipated 46 Rexahn actual 46 dispositions financings 46 Esterhazy Saskatchewan potash 46 revise anyforward looking 46 e# periodic 46 strategic reallocations 46 governmental approvals 46 Jupiterimages respective 46 concerning AudioCodes 46 impair Lillian Vernon 46 successfully commercialize Iluvien 46 Seabridge cautions 46 manufacture RISPERDAL CONSTA 46 Disruptions uncertainty 46 Oxandrin R 46 JLG acquisition 46 may diverge numerically 46 BioGlue ® 46 sublease recoveries 46 maycause actual results 46 involve anumber 46 illiquid restricted 46 b Relates 46 Newtek beliefs 46 Bioenvision filings 46 These statementsare 46 BEFORE TAXES 45 Enpath ability 45 HF Lenfest member 45 reflect events orcircumstances 45 SonoPrep device 45 Bacterin proprietary 45 affecting O2Micro 45 deCODE filings 45 Wolf Haldenstein Investigates 45 statements arebased 45 anyforward looking 45 should consult NeurogesX 45 event reporting Clintrace 45 futureperformance 45 materially impair 45 postretirement benefit plans 45 AcryMed technologies 45 Eligard R 45 DIFICID ™ 45 Idenix anticipates 45 representations warranties covenants 45 Sunesis nonclinical studies 45 mortality morbidity 45 Fampridine SR delays 45 novel emulsion formulation 45 iv unanticipated 45 adversely affecting Cubist 45 Terremark filings 45 u t 45 xvi beer 45 Invitel Holdings operates 45 please visit www.middlebrookpharma.com 45 iii iv 45 SANCTURA R 45 partner lorcaserin APD# 45 adversely affected 45 5 lipoxygenase inhibitor 45 XP# XP# 45 obtaining regulatory approvals 45 y u 45 factors thatcould 45 todiffer materially 45 KRYSTEXXA TM 45 viii insufficient 45 Laurion cautions against 45 Completes Previously Announced 45 andfinancial 45 offuture 45 mGluR2 mGluR4 mGluR5 mGluR7 45 DELETE OR EDIT COMMENTS 45 R DYNACIN R 45 PD2i Cardiac Analyzer 45 substantiate CytoCore expectations 45 r t 45 currentexpectations 45 ofany 45 Filtran Microcircuits Inc. 45 product discontinuances 45 #CL# 45 successfully integrate Legerity 45 adverse 45 CDO financings 45 muscles abdominal distension 45 n h 45 actualresults 45 technological obsolescence 45 novel proprietary KL4 45 mGluR4 mGluR2 45 Offerors Commercial applies 45 VELCADE therapy 45 xv adverse 45 Dyspepsia Tachycardia Myalgia etc. 45 BioGlue R 45 incorporate proprietary Microvolt 45 RR Donnelley periodic filings 45 R Lotrel 45 ENABLE Phase 2 45 ARLP Partnership 45 results ofoperations 45 These viruses mutate 45 BioForce Nanosciences actual 45 LogicVision disclaims 45 otherrisks 45 HYVISC R 45 FuelQuest solutions 45 Item IA 45 vii Cubist ability 45 Ambrilia views 45 SURETY LICENSES c 45 Zemiva ™ 45 securityholder approvals 45 § #.#-# [004] 45 proprietary Capillary Aerosolization Technology 45 adversely affect Linktone 45 Secure Computing periodic 45 Mitigates 45 periodic redeterminations 45 pricing pressures 45 tiny pteropod 45 AvalonBay Communities Announces 45 Nominal GDP includes 45 reflect Ronn Motor 45 Equinix filings 44 PLAVIX ® 44 Puricase PEG uricase 44 xxvi introduction 44 #,#,# Deferred [001] 44 c Reflects 44 NNL failure 44 forwarda ^ looking 44 reflect GuestLogix 44 credit carryforwards 44 natural disasters pandemics 44 theforward looking 44 APTIMA HPV assay 44 Carrier Ethernet www.soapstonenetworks.com 44 § #-#-# [005] 44 Accurel 44 CAUTIONARY STATEMENT Statements 44 looking statementsare 44 unforeseen underperformance 44 reflect VIQ Solutions 44 REMOVAL Removal shall 44 h u 44 Atheros disclaims 44 MAb therapy 44 Regains NASDAQ 44 Reported Unaudited Condensed 44 leveraging ATG 44 Epigenetics refers 44 d h 44 r h 44 BlackPearl Announces 44 OraTest R 44 further reassort 44 Bioenvision dependence 44 Multiemployer Pension Plan 44 CLX Investments 44 e h r 44 communicate differentiations effectively 44 Bioenvision compounds under 44 DISMISSED WITH PREJUDICE 44 Silver Wheaton purchases 44 EHSK 44 acquisitions mergers dispositions 44 FastFunds Financial Corporation 44 Zemiva TM Trofex TM 44 www.orchidcellmark.com 44 adversely affecting 44 favoring downsizing deinstitutionalization 44 affecting ChinaNet 44 Zi OEM 44 g Represents 44 sequencing gene expression 44 Exelixis compounds 44 futureevents 44 debt extinguishments 44 andeconomic 44 Form 8K #K 44 ExchangeCommission 44 Laich wristed 44 OmniComm intends 44 Aspyra actual 44 MOSAID litigation 44 forward.looking statements 44 EDGAR Online via COMTEX 44 g h 44 VIACOM INC. AND SUBSIDIARIES 44 Nortel Networks strategic alliances 44 #.# subd [003] 44 forward lookingstatements 44 Operations contained therein 44 LPM TM 44 f o 44 Tekmira disclaims any 44 #,#,# #,#,# -DH Ellis Burks 44 uncollectible accounts receivable 44 c SIGA 44 Kung sila pa rin 44 regulatory authorizations 44 Taleo disclaims any 44 vQsQn 44 resultsof 44 Tucows filings 44 non capitalizable 44 www.ENGlobal.com 44 STAAR assumes 44 includingstatements regarding 44 NeoPharm anticipates 44 #,#,# Commitments 44 affect NYMET Holdings 44 men bisexuals transgender 44 noticeably thinner stark 44 wagering ceasing 44 Favrille filings 44 Omtool periodic reports 44 coûts 44 Rexahn licensees 44 adversely affect NextEra Energy 44 INACCURACIES 44 ATMI undertakes 44 VIOXX Product 44 offerings visit www.balqon.com 44 eHealth ecommerce 44 adversely impacts 44 others Mannatech inability 44 Airvana anticipates 44 DJO Merger 44 Brief Profile 44 renegotiation nullification 44 p r 44 Income Tax Regs 44 LocatePLUS Statements 44 depreciation depletion amortization 44 drawing painting gouache 44 quant à 44 andother 44 novel ZFP TFs 44 TeamStaff filings 44 difficulty assimilating 44 pyrexia mucositis sepsis febrile 44 Treatment discontinuations due 44 Avivo Corporation 44 headache nasopharyngitis 44 ofnew 44 t r 44 SumTotal Systems filings 44 Oxandrin 44 oxandrolone USP 44 integrating ADVO operations 44 joint ventures divestitures 44 # wQ 44 en vertu de la 44 y h 44 Baqoubah north 44 Thelin tm 44 reflect iSIGN Media 44 please visit www.advaxis.com 44 wv ` 44 Rufino Tamayo Francisco 44 reestimates 44 distribution metabolism excretion 44 Insolvency Proceedings 44 DIP Loan 44 Iusacell Celular 44 contingently liable 43 NOL utilization 43 Heska reliance 43 intents beliefs 43 Second Supplemental Indenture 43 AudioCodes filings 43 concomitant 43 Lignol files 43 h y 43 newinformation future 43 - Adjusted [017] 43 Somewhat offsetting 43 STRIANT R 43 attributing undue 43 InfoSearch filings 43 Tasigna prolongs 43 Prospective Bidder may 43 ProPhotonix 43 CFR #.#b 43 affecting IsoTis 43 GenVec filings 43 i #.# subds 43 heading ITEM 1A 43 l w 43 USEB Chapter 43 theSecurities 43 Novavax cautions 43 intellectual property litigations 43 integrate CyVera technology 43 CEFF financings subject 43 adopting SFAS #R 43 GenVec cautions 43 successfully commercialize 43 productsand services 43 xviii currency 43 inaccuracy therein 43 http:/www.lunainnovations.com 43 Cautionary Information 43 site www.buyins.net 43 Kronos TiO2 43 competing steel minimills 43 soil fertility Kuperberg 43 Indemnity Ltd. 43 carryforwards 43 - - [092] 43 postretirement benefit 43 Aeolus Pharmaceuticals Announces 43 DiaMedica cautions 43 ThermoDox ® clinical 43 embolic coiling 43 Innodata Isogen acquires 43 Becancour facilities 43 differ materially 43 depreciation accretion 43 update anyforward looking 43 activate telomerase 43 dd DISCOUNTS R 43 Hiru Corporation ability 43 Web site http:/www.EmergingStockReport.com 43 Adverse effects 43 Pervasip actual 43 tomaintain 43 Flamel Technologies Announces 43 outbreaks epidemics 43 Unica disclaims any 43 looking statements.These 43 theavailability 43 FERC MPSC NRC 43 Daytrana TM 43 reject unexpired 43 APPY believes 43 MOSAID licensees 43 heading RISK FACTORS 43 http:/www.tripos.com 43 SmarTire cautions 43 WNS ADS 43 Innotrac Website www.innotrac.com 43 BOPET film industry 43 prescription brands RESTYLANE 43 pancreatic prostate 43 dizziness somnolence 43 THE AUCTIONEER RESERVES 43 economically recoverable coal 43 acquisitions divestitures mergers 43 Pain Neutralizer holds 43 AcryMed Incorporated 43 - - Income [012] 43 include ClindaReach TM 43 Somewhat mitigating 43 Pharmacopeia Phase 43 website www.aeroflex.com 43 NMT Medical Announces 43 Theseforward looking 43 Sepracor patents 43 principally attributable 43 AGGRASTAT R tirofiban hydrochloride 43 MorAmerica Capital 43 GEROVA underwrites insurance 43 Merger Transactions 43 ceded reinsurance 43 constituteforward looking 43 Exelbine 43 Legal #.# 43 www.palatin.com 43 geology continuity 43 Agria beliefs 43 PROCHIEVE ® 43 EcaFlo ® equipment 43 Zemiva TM 43 Estrogen deficiency 43 properties ultimate recoverability 43 Makhaya Ntini Muttiah Muralitharan 43 Textainer expectation 43 promulgated thereunder 43 STRIANT ® 43 xxiv adverse effects 43 pricing IMPAX 43 OPAXIO pixantrone 43 Somatuline R Depot 43 Nortek Holdings 43 SumTotal logo 43 www.ictgroup.com 43 explosive CBRNE 43 IoGen ™ 43 de ses 43 technology crystalline ingot 43 accounting pronouncements 43 Sunesis clinical trials 43 PDI periodic filings 43 Entereg TM 43 cranes Fuchs 43 PUBLISH THE 43 MIGENIX assumes 43 neutropenia thrombocytopenia 43 Pharmacia Monsanto 43 PAIVIS actual 43 Symphony tCGM 43 redundancy scalability 43 Partially offsetting 43 EMPOWER TM 43 ourbusiness 43 Severe hypersensitivity reactions 43 OneBeacon filings 43 g o 43 commercialize axon regeneration 43 acquisitions divestitures restructurings 43 insomnia somnolence 43 commercialize CorMedix drug 43 treat musculoskeletal metabolic 43 MFA MBS 43 satisfy indemnification obligations 43 regarding AngelCiti 43 Leverage Risk 43 PV module efficiencies 43 Macrovision assumes 43 examines Chinas 43 www.preit.com 43 XSEL beliefs 43 ATK undertakes 43 P. #a 43 CEO WE SEEK 43 unfavorably impacted 43 l o 43 DFAR #.#-# 43 visit http:/www.nationwide.com 43 results performance orachievements 43 disable virulence 43 Zanaflex Capsules 43 Ron Klauda Maryland 43 GreenHunter Energy undertakes 43 OREO valuation 43 Vicor Technologies Announces 43 renal flare 43 Osteoporotic fractures 43 candidates Azedra TM 43 http:/www.marinabio.com 42 constitutes discloseable transaction 42 risks unanticipated reclamation 42 APNB 42 c html plugins 42 [013] 42 unproved reserves 42 paroxetine sertraline 42 strategic pharmacovigilance WebVDME 42 Board Unanimously Rejects 42 u h 42 Activision Publishing maintains 42 Johnell O 42 ii Immtech ability 42 GYN Surgical revenues 42 â € œwill â 42 SIRT1 activators 42 reflect Medicago 42 Cephalon GlaxoSmithKline Organon 42 satellite datacasting market 42 Duska intends 42 date xvii Conversion 42 candidate Ramoplanin 42 liabilities slippage 42 pulls Darvon painkiller 42 Defendants misrepresented 42 similarly titled captions 42 current physiologic opioid 42 early extinguishments 42 ADAM disclaims 42 inflammatory autoimmune diseases 42 PGiSend 42 concerning VAALCO 42 gli di 42 w # yQ 42 applies prospectively 42 e mail lifestyle@readingeagle.com 42 merchant chargebacks 42 thereunder 42 Commences Offering 42 andbusiness 42 FAFLIC 42 ecotoxicity 42 governmental payors 42 didanosine associated 42 Phase III cSSSI 42 microcirculatory improvement 42 Crexendo Business Solutions 42 hypertension coronary 42 Lenfest ii 42 striped noisemakers 42 CyberDefender expectation 42 Brascan SoundVest Funds 42 dispositions joint ventures 42 visit http:/www.tronox.com 42 c Represents 42 o h 42 Sucampo Pharmaceuticals anticipates 42 Risks Related 42 dans le cadre 42 statements ofhistorical fact 42 http:/www.masimo.com 42 REIT xi 42 arising therefrom 42 SHOULD BE READ 42 angina myocardial infarction 42 please visit www.advantex.com 42 collectibility 42 SEK -#.# -#.# [002] 42 Derm ® 42 Chemed communications 42 y r 42 risks associated therewith 42 website www.gladiatorstocks.com 42 Mes amis 42 WITHDRAW ANY ITEM 42 #.# subd [006] 42 andrelated 42 dimesylate Attention Deficit 42 AirBoss Announces 42 § #.#-# [007] 42 antimetabolites 42 - - [085] 42 website www.FreePennyAlerts.com 42 w l 42 AND TO REOFFER 42 rheumatoid arthritis thrombocytopenia 42 including lacerations puncture 42 PXRE undertakes 42 relate thereto 42 collaborations Pharmacopeia 42 within themeaning 42 http:/www.adventrx.com 42 Vocus filings 42 Hyperactivity Disorder ADHD 42 AFFECT MICROSEMI 'S 42 Infor expressly disclaims 42 factors APPY 42 R Digirad Imaging 42 developing ostarine selective 42 Hemispherx involve 42 opioid tolerance 42 embargoes natural disasters 42 - - Total [039] 42 g r 42 #.#-# Instructions 42 coughing fatigue emaciation 42 iGVHD 42 OR LOSS 42 supplemental indenture effecting 42 QUADRAMET R 42 AirIQ Announces 42 Solazed TM 42 While Ambrilia anticipates 42 @ vw 42 SILENOR ™ 42 redomestication 42 retain drilling rigs 42 constitute discloseable transaction 42 visit www.targanta.com 42 inventories revalued 42 bleeding ulceration 42 CV thrombotic 42 Medicago disclaims 42 TechFaith beliefs 42 reflect Ronn Motors 42 TRISENOX 42 affect GSI Commerce 42 infringement invalidity 42 -Amos Harel Haaretz Correspondent 42 gastrointestinal GI diseases 42 militant Jihadism 42 expressively disclaims 42 morbidity mortality 42 AND OTHER RISKS DETAILED 42 NeuroMove TM 42 AUCTIONEER CONSIGNOR OR 42 successfully commercialize REOLYSIN 42 dangerously constraining 42 vascular constriction 42 CommVault beliefs 42 serum lipid 42 Assumptions underlying 42 Entereg R 42 lumpiness persistent swelling 42 Partially offset 42 HS Orka geothermal 42 assorted pigments resins 42 applicable dayrates 42 b Reflects 42 @ vn 42 Administaff filings 42 theimpact 42 Comarco Announces 42 Knoxville MSA 42 Ambrilia specifically 42 unmeasured confounding 42 adversely affect FPL 42 hoFH 42 uncertainties 42 Kyowa Kirin 42 detrimentally affected 42 www.pdi inc.com 42 shape zeta 42 3Q FY# representing 42 biomimetics non 42 Variable annuities involve 42 Yima project 42 TranSwitch filings 42 PROVISIONS OF THE PRIVATE 42 Announce Monthly Distributions 42 Atheros Annual Report 42 AMPS Risk 42 Cytec Announces 42 RAPTIVA R 42 Phase III LibiGel 42 AnnualReport 42 directionally consistent 42 Kayoko Kano acknowledged 42 Alpine Skiing Riding 42 nervousness irritability 42 include sutures needles 42 DARA intellectual property 42 thereby adversely affecting 42 www.cytomedix.com 42 without uremia 42 Announce Termination 42 novel orally inhaled 42 regarding allosteric modulators 42 should consult Cytokinetics 42 reduced workforces scarcity 42 Refinancing Transactions 42 SEK -#.# -#.# [003] 42 READERS SHOULD NOT 42 Tronox Annual Report 42 indications Cytokinetics 42 concerning Wowjoint 42 unfavorable variances 42 Carnoustie Turnberry Royal Troon 42 Salary.com expressly disclaims 42 novel L DOS# 42 cMET inhibitor 42 reflect Sentry Select 42 JM Dutton adds 42 evaluating Questcor 42 strong CYP#A# inducers 42 Blowouts onshore Fear 42 resins polymers 42 w r 42 MTHFD1L gene 42 hypertension pulmonary arterial 42 PAIVIS intends 42 Waratah Coal filings 42 materially overstated 42 affect Zygo Corporation 42 opioid bowel dysfunction 42 Foundry Model private = modelName 42 S ROSE HILL 42 cardiovascular thrombotic 42 PURPOSE OF SAFE HARBOR 42 Medicure Announces 42 Goodwill impairment charge 42 Goggin holed 42 worsening peripheral neuropathy 42 Illiquidity Risk 42 QLT Annual Report 42 OR INFORMATION 42 Tripos logo 42 Unexplained muscle 42 nasopharyngitis headache 42 microsurgical disciplines 42 Oligator R oligonucleotides iv 42 CHDT SEC Filings 42 VeraTag assays 42 factorsthat 42 PD2i ® algorithm 42 #.#-# #.#-# #.#-# #.#-# 42 SCHIP Extension 42 esophagus bladder 42 Largely offsetting 42 Azedra TM Onalta TM 42 hyperinflationary environments 42 negatively affect 42 vendor unseasonable weather 42 Farmstead Telephone 42 sNDAs 42 DYNACIN R Tablets 42 HERmark assay 42 negations thereof generally 42 free E Newsletters